Search the Newsreel

Certara earnings up next: Can AI strategy stem revenue decline? By Investing.com

Certara, a biosimulation software provider, is set to report its second-quarter results, with analysts expecting an EPS increase but a 6% revenue decline year-over-year. Investors will be watching whether the company's new leadership and AI-focused strategy, including a partnership with NVIDIA and increased R&D …

Tara Chand Infralogistics Solutions Q1 Results: Earnings Call Scheduled for Aug 7

ETFs Investing in Atara Biotherapeutics Inc Stocks

This article lists ETFs that hold stocks of Atara Biotherapeutics Inc. It highlights that these ETFs offer more accessible investment opportunities with lower risk. One specific ETF, the BUSM EA Bridgeway Ultra-Small Company Market ETF, is detailed with its market value, weight in Atara …

Tarapur Transformers Limited Revenue Breakdown – NSE:TARAPUR

Certara Inc (CERT) Institutional Confidence

Certara Inc (CERT) has an institutional shareholding score of 10.00, placing it first in the Software & IT Services industry. The institutional shareholding proportion is 115.63%, a decrease of 12.27% quarter-over-quarter. Bill Nygren | OAKMX is the largest institutional shareholder, holding 1.51M shares, representing …

Syntara Limited 2026 Q4 - Results - Earnings Call Presentation (OTCMKTS:PMXSF) 2026-07-31

Protara Therapeutics Inc (TARA) Valuation: PE, PB & Fair Value Analysis

Protara Therapeutics Inc (TARA) has a current valuation score of 6.67, placing it 292nd out of 384 in the Biotechnology & Medical Research industry. Its P/E ratio is -2.97. However, key P/B and P/CF data have not yet been disclosed by the company.

Protara Therapeutics Inc (TARA) Financial Health: Profitability & Balance Sheet Analysis

Protara Therapeutics Inc (TARA) has a robust financial status with a current financial score of 7.14, ranking 147 out of 384 in the Biotechnology & Medical Research industry, though its operating efficiency is low. The article provides an overview of various financial indicators, including …

Certara Inc (CERT) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Certara Inc (CERT), noting its current valuation score of 9.16 within the Software & IT Services industry. It highlights the company's P/E ratio, which stands at -85.20, and mentions that relevant data for P/B, P/S, and P/CF …

Certara Number of Employees 2026 | Employee Count & Headcount Data

Certara, Inc. (CERT) has approximately 1,618 total employees worldwide as of March 2026, representing a 4.9% growth from 1,542 employees in 2023. The company is actively hiring, although job postings have declined by 19.4% in 2026 compared to 2025. Certara's workforce is concentrated in …

Atara Biotherapeutics Inc (ATRA) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Atara Biotherapeutics Inc (ATRA), detailing its current risk assessment score, beta value, and various volatility and financial metrics. ATRA has a risk score of 2.51, ranking 210 out of 385 in its industry, and a beta of …

Certara, Inc. (CERT) Stock Analysis: A Healthcare Investment With Limited Upside Potential

Certara, Inc. (CERT) is a significant player in the health information services industry, offering biosimulation solutions for drug discovery and clinical research. Despite its innovative technology and robust free cash flow, the company is not currently profitable, with negative EPS and return on equity. …

Syntara (ASX:SNT) Banks Parkinson's Milestone and Capital Raise

Certara Inc (CERT) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Certara Inc (CERT), detailing its current price momentum score, support and resistance levels, and various technical indicators. It shows that CERT's stock price is trading between resistance at $8.68 and support at $6.70, suggesting suitability for range-bound …

CERT|Certara Inc|Price:7.915|Chg%:+0.165

This article provides a comprehensive stock analysis of Certara Inc (CERT) by TradingKey, focusing on its fundamentals, valuation, growth potential, and institutional ownership. It highlights Certara's healthy fundamentals and high growth potential, classifying its valuation as fairly valued within the Software & IT Services …

ATRA|Atara Biotherapeutics Inc|Price:7.680|Chg%:-0.130

This article provides a comprehensive stock analysis of Atara Biotherapeutics Inc (ATRA) by TradingKey, highlighting its "fairly valued" status within the Biotechnology & Medical Research industry and significant growth potential. The company's fundamentals are stable, with high institutional ownership and multiple "Buy" ratings from …

Certara Inc (CERT) Income Statement

This article provides the quarterly and annual income statements for Certara Inc (CERT), offering detailed financial data including total revenue, operating expenses, net income, and earnings per share from FY2019Q3 through FY2026Q1. It also includes an FAQ section to help users understand how to …

Certara (CERT) to Announce Earnings on Tuesday

Pendapatan Selaras Citra (SCNP) Naik 41,75% Jadi Rp 156,58 Miliar per semester I-2026

Atara Biotherapeutics Inc (ATRA) Valuation: PE, PB & Fair Value Analysis

Atara Biotherapeutics Inc (ATRA) currently holds a valuation score of 7.36, ranking 225th out of 385 companies in the Biotechnology & Medical Research industry. Its P/E ratio is -5.53, significantly below its recent high and above its recent low. Key valuation metrics like P/B, …

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Atara Biotherapeutics, Inc. (ATRA) and Encourages Shareholders to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Atara Biotherapeutics, Inc. (ATRA) for potential corporate wrongdoing. The firm is encouraging shareholders who purchased Atara securities before May 20, 2024, and still hold them, to join the investigation. The investigation aims to recover …

Atara Biotherapeutics Inc (ATRA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article from TradingKey provides an overview of Atara Biotherapeutics Inc (ATRA), including its current stock price and market capitalization. It highlights that detailed revenue breakdown data by business segment and region have not been disclosed by the company. The page serves as a …

TARA|Protara Therapeutics Inc|Price:3.938|Chg%:-0.102

This article provides a comprehensive stock analysis of Protara Therapeutics Inc (TARA) from TradingKey, highlighting its strong fundamentals and high growth potential. The company's valuation is considered fairly valued within the Biotechnology & Medical Research industry, with high institutional ownership and multiple Buy ratings …

Protara Therapeutics Inc (TARA) Institutional Confidence

Protara Therapeutics Inc (TARA) has an institutional shareholding score of 7.00, placing it 80th in the Biotechnology & Medical Research industry. The institutional shareholding proportion is 85.08%, which is a 61.63% increase quarter-over-quarter. Steven Cohen is the largest institutional shareholder, holding 1.26 million shares.

Atara Biotherapeutics Inc (ATRA) Financial Health: Profitability & Balance Sheet Analysis

Atara Biotherapeutics Inc (ATRA) has a weak financial status with a current financial score of 5.52, ranking low in the Biotechnology & Medical Research industry. The company's latest quarterly revenue decreased by 99.47% year-over-year, and its net profit decreased by 110.91% year-over-year. Several key …

Walleye Capital LLC Boosts Position in Protara Therapeutics, Inc. $TARA

Walleye Capital LLC significantly increased its stake in Protara Therapeutics, Inc. (NASDAQ:TARA) by 204% in the first quarter of 2026, bringing its total holdings to 443,401 shares valued at $2.31 million. Other institutional investors also modified their positions, with hedge funds and institutional investors …

Certara Inc (CERT) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Certara Inc (CERT), detailing its current earnings forecast score, average price target, and analyst ratings. Based on 13 analysts, the consensus is to "Hold" the stock, with an average price target of $13.50. The article also includes …

Certara Inc (CERT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a revenue breakdown for Certara Inc (CERT), detailing its regional revenue contributions. As of the stated update, the Americas account for the largest share at 69.62% ($291.60 million), followed by EMEA at 22.12% ($92.63 million), and Asia Pacific at 8.26% ($34.61 …

Protara Therapeutics Inc (TARA) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides details on the dividend and stock split history for Protara Therapeutics Inc (TARA). It states that the company has not distributed any dividends over the past five years. Key financial data like market cap and current stock price are also presented.

Protara Therapeutics Inc (TARA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article from TradingKey provides a revenue breakdown for Protara Therapeutics Inc (TARA). It states that relevant data regarding business segments, regional revenue, and profit contribution for FY2019 have not been disclosed by the company yet. The article indicates a market cap of $222.36 …

Atara Biotherapeutics (ATRA) director affiliate exercises pre-funded warrants

Funds managed by Redmile Group, LLC, an affiliate of an Atara Biotherapeutics director, exercised pre-funded warrants for ATRA common stock via a cashless exercise on July 22, 2026. This transaction resulted in the funds receiving 195,211 shares, with 60 shares withheld to cover the …

ATRA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc

Bronstein, Gewirtz and Grossman, LLC has announced a class action lawsuit against Atara Biotherapeutics, Inc. (NASDAQ:ATRA). The lawsuit, filed on behalf of investors who purchased Atara securities between May 20, 2024, and January 9, 2026, alleges that the company made false and misleading statements …

PT Sarana Menara Nusantara Tbk Revenue Breakdown – IDX:TOWR

PT Nusantara Sawit Sejahtera Tbk Revenue Breakdown – IDX:NSSS

Does TARA Stock’s 15% After-Hours Slump Signal A Bargain After New Bladder Cancer Data?

Protara Therapeutics (TARA) saw its stock drop nearly 15% after hours despite reporting strong efficacy and a favorable safety profile from its Phase 2 Advanced-2 bladder cancer trial. The data showed high complete response rates in both BCG-unresponsive and BCG-naive patients. Analysts remain bullish …

PT Abadi Nusantara Hijau Investama Tbk Revenue Breakdown – IDX:PACK